TransMedics Group, Inc. (TMDX) fair value analysis
Nasdaq · Updated 2026-10-19
TMDX price how computed
Forward Fair Value verdict
UndervaluedTMDX is trading at more than a 25% discount to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $70.78
- Sector
- Healthcare
- 12-month range
- $62.04–$150.42
- Market cap
- $2.45B
- From 52-week high
- -52.9%
- Shares outstanding
- 34.7M
- Rank in Healthcare by discount to fair value
- #100 of 108
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
TransMedics Group, Inc. is a medical device company that develops and commercializes organ preservation and transport systems designed to extend the viability of organs for transplantation. The company operates internationally, serving transplant centers and organ procurement organizations in multiple countries.
TMDX currently ranks #100 of 108 Healthcare stocks by discount to fair value. It has screened as Undervalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $2.45B
- P/E (trailing)
- 49x
- Revenue (TTM)
- $668M
- Net margin
- 22.7%
- EPS (TTM)
- $1.45
- Gross margin
- 59.6%
- Debt / equity
- 1.67
- Revenue growth (3-yr avg)
- 62.0%
- Shares outstanding
- 34.7M
Derived indicators how computed
- Quality grade
- B
- Margin trend
- Stable
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 28 · oversold
- 50-day average
- $85.43
- 200-day average
- $97.64
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Earnings how computed
- Next earnings report
- 2026-11-04
- Last 8 quarters vs consensus
- 3 beat, 5 missed
- Quarter by quarter
- 2026-06 ▼ miss (-12.0%)
2026-03 ▼ miss (-50.8%)
2025-12 ▼ miss (-86.9%)
2025-09 ▲ beat (+83.3%)
2025-06 ▲ beat (+114.0%)
2025-03 ▲ beat (+191.7%)
2024-12 ▼ miss (-13.6%)
2024-09 ▼ miss (-62.5%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 8 buy · 4 hold · 0 sell (12 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $98.7
- Target vs last price
- +39.4%
What our data shows for TMDX
- Our model validated 7 trailing price-to-earnings windows for TMDX, built from quarterly earnings records.
- Shares are trading in the lower third of their 12-month price range of $62.04–$150.42.
- The 14-day relative strength index sits at an oversold 28.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for TMDX
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent TMDX news
TickrTrends' derived news-sentiment signal for TMDX is currently leaning positive, computed from recent coverage.
- A Look at TransMedics Group Inc (TMDX) After 4.4% Gain -- GF Value $160.62 vs Price $74.75 (gurufocus.com, 2026-10-21)
TickrTrends take: TransMedics Group Inc operates in the Healthcare sector and is currently trading at a significant discount to its GF Value estimate, which aligns with TickrTrends' Undervalued designation. The gap between the estimated fair value and current trading price suggests the stock may warrant attention from investors focused on valuation metrics, though such discrepancies can persist for various reasons including market sentiment, growth expectations, or risk assessments. Valuation-focused readers should monitor whether this gap narrows over time and what fundamental developments might influence the company's actual value relative to market pricing. - TMDX Maintained by Canaccord Genuity -- Price Target Lowered to $94 (gurufocus.com, 2026-10-13)
TickrTrends take: Canaccord Genuity's reduction of its price target to $94 occurs within a context where TickrTrends currently identifies TMDX as undervalued, suggesting the market may not yet be pricing in the full value of the Healthcare company's assets or earnings potential. A valuation-focused reader should monitor whether this analyst action represents a broader market reassessment that could narrow the gap between current pricing and intrinsic value estimates. The maintenance rating alongside the lowered target warrants attention to whether upcoming earnings or operational metrics might validate or challenge the undervalued designation. - TransMedics Group Inc (TMDX) Stock Up 4.0% and Still Undervalued -- GF Score: 72/100 (gurufocus.com, 2026-10-06)
TickrTrends take: TransMedics Group Inc operates in the Healthcare sector where operational efficiency and revenue growth trajectories significantly influence valuation multiples. The stock's recent 4 percent gain alongside TickrTrends' undervalued designation suggests that market pricing has not yet fully reflected the company's fundamentals relative to sector comparables. Investors focused on valuation should monitor whether TMDX's GF Score of 72 out of 100 translates into sustained price discovery, particularly if Healthcare sector momentum accelerates or if the company demonstrates improved operating margins.
More TMDX news
- TransMedics Group Inc (TMDX) Shares Fall 5.8% -- What GF Score of 74 Tells Investors (gurufocus.com, 2026-10-02)
- A Look at TransMedics Group Inc (TMDX) After 3.0% Decline -- GF Value $159.18 vs Price $82.73 (gurufocus.com, 2026-09-29)
What people are saying
Follow the TMDX conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — TickrTrends' derived indicators for TMDX showed movement this week as the Relative Strength Index shifted from the neutral zone into oversold territory, suggesting the stock has experienced downward momentum. The current valuation verdict remains Undervalued, indicating the stock may be trading below levels suggested by fundamental metrics.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — TMDX moved into a downtrend this week as its 50/200-day trend state shifted from mixed to downtrend. The stock's sector discount rank improved to number 29 from number 36, indicating it is trading at a better discount relative to other healthcare sector companies. Despite the negative trend shift, TMDX remains valued as undervalued according to current assessment.
- 2026-09-28 — TMDX's derived indicators shifted this week as the 50/200-day trend state moved from downtrend to mixed, while momentum indicators declined from a B rating to none. The stock currently registers as undervalued according to TickrTrends' valuation assessment. These changes reflect a transition in the company's technical positioning within the Healthcare sector.
- 2026-09-21 — TMDX's technical trend indicators shifted this week, with the 50/200-day moving average relationship moving from a mixed state into a downtrend configuration. The stock maintains an undervalued valuation verdict according to TickrTrends' derived metrics. This downward trend development represents a notable change in the near-term momentum picture for the healthcare sector company.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is TMDX stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), TMDX is trading at more than a 25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.
What is TMDX's TickrTrends verdict?
TMDX's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.
How does TMDX compare to other Healthcare stocks?
TMDX ranks #100 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is TMDX overbought or oversold?
TMDX's 14-day RSI is in the oversold zone on TickrTrends' latest weekly data.
When does TMDX report earnings next?
TMDX's next earnings report is scheduled for 2026-11-04, per the published earnings calendar.
Does TMDX usually beat earnings estimates?
Over its last 8 reported quarters TMDX beat the consensus estimate 3 times and missed 5 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about TMDX?
Of 12 analysts covering TMDX, 8 rate it a buy, 4 a hold and 0 a sell - buy-leaning, with a consensus price target of $98.7 (+39.4% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
TMDX vs DXCM · TMDX vs EMBC · TMDX vs IDXX · TMDX vs INDV · TMDX vs LMAT